Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.75
Bid: 13.50
Ask: 14.00
Change: -0.25 (-1.79%)
Spread: 0.50 (3.704%)
Open: 14.00
High: 14.00
Low: 13.75
Prev. Close: 14.00
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Geomerics IP Validation

27 Jul 2006 07:00

Angle PLC27 July 2006 For Immediate Release 27 July 2006 ANGLE plc ("ANGLE") Core intellectual property validation: Geomerics Ltd ("Geomerics") ANGLE, the venture management and consulting company specialising in thecommercialisation of technology, is pleased to announce the validation ofProgeny(R) company Geomerics' core intellectual property through demonstrationof a revolutionary new computer graphics technology. Geomerics has unveiled technology that allows real-time radiosity in computergames utilising commodity graphics processing hardware. Radiosity, the processof fully modelling the subtle effects arising from the inter-reflections oflight between surfaces, dominates many real-world situations. Until now, sucheffects were considered beyond the reach of real-time techniques producingnoticeably 'unrealistic' lighting in computer games. Geomerics' breakthrough dynamic radiosity solution enables the full range oflighting effects, including inter-reflections, to be updated in real-time,providing significantly greater realism and impact. Geomerics has applied itscore intellectual property, based around geometric algebra, to produce thisradical new radiosity solution. The solution allows for fully dynamic lighting,including point spot-lights, area lights, texture-based lighting, glowingobjects and the projection of video onto geometry, all on common video hardware. Geomerics provided the first live demonstration of the technology at the DevelopConference in Brighton on 13 July. ANGLE is pleased to announce that subsequentindustry response to the technology was considerable, with over fifty commercialenquiries including many leading games developers. ANGLE believes that thisdemonstration is a validation of the power of Geomerics' core intellectualproperty and looks forward to both further applications and imminent commercialvalidation. Further details, including screenshots, movies, and previews of other Geomericssolutions can be found at www.geomerics.com Chris Doran, CEO and founder of Geomerics commented, "This revolutionarylighting technique is a demonstration of the potential of Geomerics' technologyand our unique approach to games middleware and technology licensing. Geometricalgebra provides opportunities for totally new solutions in a huge range ofgames problems, from lighting to physics and beyond." Andrew Newland, CEO of ANGLE, commented, "We are excited to view the validationof Geomerics' core intellectual property. The company has made good progress todate and we look forward to further applications of the core intellectualproperty in the near future." Geomerics, founded by ANGLE in 2005, is commercialising geometric algebratechnology developed at the University of Cambridge, UK, and in the USA. Thistechnology has applicability in the computer games industry, where it enablesfilm-quality visuals to be generated in real-time; in electromagnetic modelling,where a step-change in accuracy and speed can be seen; and in a wide selectionof other industries, to be announced by the company in due course. Geomerics is an ANGLE Progeny(R) Company. For further information ANGLE plc +44 1483 295830Andrew Newland, Chief ExecutiveStephen Bence, Director of New Ventures GeomericsAlison Beasley of Lincoln Beasley PR +44 1608 645756 Buchanan CommunicationsRichard Darby, Amy Rajendran +44 207 466 5000 Note to editors: About ANGLE Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE operates from officesin the UK, the US and the Middle East. ANGLE is listed on AIM (AGL.L); further information can be found atwww.angleplc.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
22nd Dec 20157:00 amRNSCompletion of Geomerics Transaction
15th Dec 20157:00 amRNSParsortix first commercial sales
10th Dec 20157:00 amRNSChange of FTSE Industry Classification Benchmark
30th Nov 20155:56 pmRNSHolding(s) in Company
17th Nov 20157:00 amRNSLung Cancer Research Publication
12th Nov 20152:17 pmRNSISSUE OF SHARE OPTIONS
14th Oct 20157:00 amRNSPatent Grant
30th Sep 20155:50 pmRNSResult of AGM
28th Sep 20157:00 amRNSOvarian cancer results
24th Sep 20157:00 amRNSProstrate cancer study published PLOS ONE Journal
9th Sep 20157:00 amRNSBREAST CANCER RESULTS PRESENTED AT CDX CONFERENCE
8th Sep 20153:54 pmRNSAnnual Report and Accounts and Notice of AGM
26th Aug 20151:48 pmRNSIssue of Equity and Total Voting Rights
23rd Jul 20157:00 amRNSFinal Results
20th Jul 20157:00 amRNSNotification of Preliminary Results
8th Jul 20157:00 amRNSAppointment Of Scientific Adviser
11th Jun 20157:00 amRNSBarts Prostate Cancer Update
3rd Jun 20157:00 amRNSAppointment of Scientific Adviser
26th May 20157:01 amRNSNew Patent Grants
21st Apr 20157:00 amRNSOvarian Cancer Update
20th Apr 20157:00 amRNSSidney Kimmel Cancer Centre
14th Apr 20157:00 amRNSIssue of Equity
4th Mar 20157:00 amRNSOffer to Shareholders
25th Feb 20151:11 pmRNSIssue of Equity
20th Feb 20154:05 pmRNSHolding(s) in Company
16th Feb 20157:01 amRNSMD Anderson Collaboration
16th Feb 20157:00 amRNSPlacing, Subscription and Offer
29th Jan 20157:00 amRNSInterim Results
27th Jan 20157:01 amRNS"Unprecedented Specificity" in Ovarian Cancer
23rd Jan 20157:00 amRNSCorporate Collaboration
23rd Jan 20157:00 amRNSPointMan collaboration with ANGLE plc
21st Jan 20153:00 pmRNSFurther information re Director's share transfer
19th Jan 20157:00 amRNSNotification of Interim Results
8th Jan 20157:00 amRNSCorporate Collaboration
15th Dec 20147:00 amRNSCancer Research Manchester Institute Publication
12th Nov 20147:00 amRNSFurther information re Director's share transfer
10th Nov 20147:00 amRNSIssue of Share Options
31st Oct 20147:00 amRNSADR PROGRAMME
21st Oct 20147:00 amRNSDirector's Share Transfer
17th Oct 20147:00 amRNSCollaboration with Barts Cancer Institute
17th Oct 20147:00 amRNSKey Opinion Leaders Report on Parsortix System
30th Sep 20144:30 pmRNSResult of AGM
30th Sep 20147:00 amRNSCollaboration with Thomas Jefferson University
25th Sep 20147:00 amRNSADR Programme, FDA Update and US Appointment
19th Sep 20147:00 amRNSBreast Cancer Collaboration
17th Sep 20147:00 amRNSCollaboration with Medical University of Vienna
8th Sep 20147:00 amRNSHamburg-Eppendorf Collaboration
4th Aug 20147:00 amRNSParsortix Granted Second US Patent
23rd Jul 20147:00 amRNSPreliminary Results
22nd Jul 20147:00 amRNSParsortix Evaluation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.